BOOTH # 6 – SMITH & NEPHEW

Collagenase Santyl Ointment: an Active Enzymatic Debriding Therapy

- SANTYL® Ointment is a Health Canada Approved prescription active enzymatic therapy that continuously removes necrotic tissue from wounds at the microscopic level. This works to free the wound bed of microscopic cellular debris, allowing granulation to progress and epithelialization to occur* SANTYL® Ointment is indicated for the debridement of*:

- Pressure Ulcers
- Diabetic ulcers
- Venous leg ulcers
- Severely burned areas
- SANTYL[®] ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase.

SANTYL[®] Ointment has been proven clinically efficacious in a number of studies in a variety of wound types*:

- Demonstrated superiority to placebo in the debridement of dermal ulcers
- Demonstrated superiority to standard antimicrobial therapy alone and combination with topical antimicrobial therapy in the debridement of severe burns
- Well tolerated in the debridement of both soft tissue ulcers and severe burns

* Full reference list available upon request

Contact Information:

David Parsons Associate Territory Sale Manager Advanced Wound Biotherapeutics Ontario West and Atlantic Canada T: 416 301 8378 E: <u>David.parsons@smith-nephew.com</u>

W: www.smith-nephew.com / www.santyl.ca

Anna Ricci Executive Sales Representative Advanced Wound Biotherapeutics Ontario East T: 416 948 0461 E: anna.ricci@smith-nephew.com

